CAJ | 학술논문

目的：探讨TIP30在表皮生长因子受体-2（HER-2）阳性乳腺癌患者癌组织中表达及临床意义。方法选择接受过生物化疗（曲妥珠单抗联合紫杉醇）的HER-2阳性晚期乳腺癌患者53例，采用免疫组化法检测患者癌组织中的TIP30表达，并分析其表达与患者临床病理特征及临床疗效的关系。结果 TIP30在HER-2阳性乳腺癌组织中阳性表达率为56．6％，TIP30表达与患者的年龄、病理类型、转移部位数量及雌激素受体、孕激素受体表达无关，而与功能状态评分及临床疗效相关（P均＜0．05）。53例患者化疗2个周期后，临床获益（CB）29例（CB率为54．7％）。30例TIP30阳性表达的患者中，CB 22例（73．3％）；23例TIP30阴性表达的患者中，CB 7例（30．4％），两者CB率比较P＜0．05。 TIP30表达阳性、阴性患者的中位无进展生存期分别为11．47、4．87个月，两者比较P＜0．01。结论 TIP30在HER-2阳性晚期乳腺癌患者癌组织中表达下调可能与预后不良有关，其可能作为该类患者生物化疗的疗效预测指标之一。
목적：탐토TIP30재표피생장인자수체-2（HER-2）양성유선암환자암조직중표체급림상의의。방법선택접수과생물화료（곡타주단항연합자삼순）적HER-2양성만기유선암환자53례，채용면역조화법검측환자암조직중적TIP30표체，병분석기표체여환자림상병리특정급림상료효적관계。결과 TIP30재HER-2양성유선암조직중양성표체솔위56．6％，TIP30표체여환자적년령、병리류형、전이부위수량급자격소수체、잉격소수체표체무관，이여공능상태평분급림상료효상관（P균＜0．05）。53례환자화료2개주기후，림상획익（CB）29례（CB솔위54．7％）。30례TIP30양성표체적환자중，CB 22례（73．3％）；23례TIP30음성표체적환자중，CB 7례（30．4％），량자CB솔비교P＜0．05。 TIP30표체양성、음성환자적중위무진전생존기분별위11．47、4．87개월，량자비교P＜0．01。결론 TIP30재HER-2양성만기유선암환자암조직중표체하조가능여예후불량유관，기가능작위해류환자생물화료적료효예측지표지일。
Objective To explore the expression of TIP 30 in epidermal growth factor receptor-2 ( HER-2 )-positive advanced breast cancer and its clinical significance. Me thods The expression of TIP30 was detected in 53 HER-2-positive advanced breast cancer tissues by immunohistochemistry .The tissues were obtained before biochemotherapy by Herceptin plus taxol ( TAX) .The relationship with clinicopathological parameters and biochemotherapy response was analyzed .Re-sults The positive expression rate of TIP30 was 56.6%in HER-2-positive advanced breast cancer tissues .There was no correlation between the expression of TIP30 protein and age, pathological pattern, metastasis, estrogen receptor (ER), and progestrone receptor ( PR) , but the expression of TIP 30 was associated with the functional status score and clinical efficacy (all P<0.05).After two cycles of biochemotherapy , the clinical benefit rate (CBR) was 54.7%.In 30 patients with positive TIP30 expression, the CBR was 73.3%(22/30), by contrast, the CBR was only 30.4%in 23 patients with neg-ative TIP30 expression, which showed a significant difference between the two groups (all P<0.05).The median progres-sion-free survival time was 11.47 and 4.87 months in patients with positive TIP30 expression and negative TIP30 expres-sion, respectively (all P<0.01).Conclusion The down-regulated TIP30 expression in HER-2-positive advanced breast cancer may be associated with the poor prognosis , which could be an important biomarker in predicting the efficacy of bio-chemotherapy in patients with HER-2-positive advanced breast cancer .